The company Amferia, based on research from Chalmers, announcing that its antibacterial peptide based wound dressing has been granted approval by the U.S. Food and Drug Administration (FDA) through the De Novo Classification Request track. This allows Amferia to enter the U.S. market with a unique Class 2 medical device antibacterial dressing for advanced wound care.
Antimicrobial resistance is accelerating at a pace that threatens to become one of the leading causes of human mortality worldwide in coming decades. Antibacterial peptides is one of the promising class of antimicrobials to address resistance. Amferia’s breakthrough is the development of a hydrogel platform, encasing antibacterial peptides in a solid protective gel. This design shields the vulnerable facets of peptides while allowing their bacteria-killing structures to remain exposed and lethal to even antibiotic-resistant bacteria.
Antibacterial peptides are known for their ability to kill bacteria due to their positive electrostatic charge, which attracts the negatively charged infectious bacteria. This allows peptides to puncture bacterial membranes and destroy the cells. However, their fragility in biological environments has been a major challenge to developing peptides as a viable treatment, naturally occurring enzymes in the body can destroy them within seconds. The Amferia hydrogel technology solves that problem.
“Bacterial infections are likely to surpass cancer and heart disease as a number one cause of human deaths in the future, and this is largely due to resistance to commonly used antibiotics. The hydrogel technology enables the safe and stable use of antibacterial peptides, allowing them to effectively target bacteria without harming surrounding tissue”, says Anand Rajasekharan, Amferia CEO & Co-Founder.
The approval opens new doors
The FDA’s approval of Amferia’s innovation establishes a new regulatory category for wound dressings and enables a unique and powerful tool in the worldwide battle against wound infection. The FDA’s decision positions Amferia as a strategic partner for established wound care companies seeking next-generation antimicrobial solutions that align with evolving regulatory and safety expectations. Amferia now expects heightened interest from industry partners and plans to expand the application of its peptide-based technology beyond wound care over time.
“This approval validates years of scientific and regulatory work and is an important milestone for an innovation that was born out of Chalmers from our PhD projects” says Rajasekharan.
Amferia has the potential to reduce infection rates, lower healthcare costs, and provide new options for treating wounds where conventional antimicrobials are becoming less effective.
The company has already entered the animal health segment and signed commercial agreements with leading animal health companies in Europe to introduce a wound dressing that also kills resistant bacteria and is now expanding into new markets with further partnerships.